Investor relations
We are a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.
Press releases
March 03, 2021
Novamind Expands Leadership Team, Accelerating M&A
March 01, 2021
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
February 23, 2021
Novamind to Present at Benzinga Conference
February 22, 2021
Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF
Novamind Inc.
CSE:NM
Share capitalization
Issued & outstanding: 40,200,767
Reserved for issuance: 7,887,792
Financial statements and public disclosure documents
| Year | Quarter | Date | Report | Download |
|---|---|---|---|---|
| 2021 | Q1 | March 1, 2021 | Interim Financial Statements | View PDF |
| 2021 | Q1 | March 1, 2021 | Management’s Discussion and Analysis | View PDF |
| 2020 | Q4 | December 31, 2020 | Filing Statement | View PDF |
| 2020 | Q4 | November 12, 2020 | Material Change Report | View PDF |
| 2020 | Q3 | July 3, 2020 | Material Change Report | View PDF |
To view Novamind's full financial disclosures, please visit SEDAR
Advisors
Transfer agent
Marrelli Trust Company Limited
Legal Counsel
McMillan LLP
Auditor
DMCL LLP
Interested in investing? Contact IR@novamind.ca